Pioglitazone

Limits on what this shows

• Key negative/null findings: Placebo group showed no change over the same 12 weeks, supporting drug attribution rather than time-related drift.
• At-risk subgroups: Studied specifically in type 2 diabetes with baseline mitochondrial DNA deficits relative to non-diabetic controls; effect size in non-diabetic or well-controlled populations is not established.
• Counter-evidence on record: None identified for pioglitazone specifically; this review could not independently verify a supporting animal (rat, diabetic atrium) study found in search listings because the source could not be opened, so it is not used as corroboration here.

Regulatory status

Not addressed in the FDA label.

Population evidence

RCT, 48 people with type 2 diabetes (pioglitazone 45 mg/day vs. placebo, 12 weeks) plus 12 non-diabetic controls. Pioglitazone restored adipose mitochondrial DNA copy number to control levels; PGC-1α expression rose (p<0.01), mitochondrial transcription factor A rose (p<0.05), citrate synthase activity rose from 6.07±0.3 to 8.19±0.9 μmol·min⁻¹·g tissue⁻¹ (p<0.05). Bogacka I, Xie H, Bray GA, Smith SR. Diabetes 2005;54(5):1392-1399.

Mechanism

Named: PPAR-γ agonism driving PGC-1α/mtTFA-mediated mitochondrial biogenesis and fatty-acid oxidation gene expression in adipocytes.

Counter-evidence held on record

This is a reverse-direction (protective) finding, not a burden. No supplement or intervention is implied; it is listed because the seven-category protocol requires grading this category regardless of direction.

Limits on what this shows

• Key negative/null findings: Protein carbonyls unchanged in the transplant-recipient RCT; no significant monotherapy effect on TOS/OSI in the second study; IMA rose in both arms of that study.
• At-risk subgroups: The clearest positive signal (MDA reduction) is in a narrow, high-risk population (diabetic kidney-transplant recipients) and has not been shown to generalize.
• Counter-evidence on record: Recorded above (null TPC result; null monotherapy TOS/OSI result; paradoxical IMA rise). This review's source for finding (2) is a secondary commentary discussing the primary study rather than the primary paper itself, opened directly during this review; the primary paper's full results were not independently re-verified.

Regulatory status

Not addressed in the FDA label.

Population evidence

(1) Triple-blind, placebo-controlled RCT, 62 diabetic kidney-transplant recipients, 4 months: malondialdehyde (MDA) fell significantly with pioglitazone vs. rose with placebo (between-group p<0.0001, 95% CI 1.22-3.90); total protein carbonyls unchanged (p=0.98) ( SEMJ /Brieflands 2024). (2) A separate 12-week RCT in general type 2 diabetes (reported via a 2024/2025 commentary on the original Temiz Gençoğlu et al. study) found a significant reduction in TOS and OSI only for the metformin-pioglitazone combination, no significant difference between pioglitazone monotherapy and comparator arms, and an unexpected rise in ischemia-modified albumin in both groups.

Mechanism

Plausible: PPAR-γ agonism has documented anti-inflammatory and antioxidant-adjacent transcriptional effects, but the human data above do not show a single consistent marker or population.

Counter-evidence held on record

Labeled explicitly as conflicting. Not a basis for an antioxidant-supplement claim in either direction.

Limits on what this shows

• Why no grade: Both conditions for ungraded were met: no Tier B or Tier C evidence was found linking pioglitazone to copper status at any level, and no circulating consumer claim naming pioglitazone and copper was found either. Multiple query phrasings were tried across PubMed search listings and web search ("pioglitazone copper ceruloplasmin," "pioglitazone copper zinc trace element serum," "pioglitazone copper") across more than one host; the pioglitazone-specific results returned were unrelated (copper-catalyzed chemistry syntheses, unrelated drug-repurposing hits). No mechanism from Steps 1-2 (no chelation, no renal copper wasting, no GI mucosal injury) implicates copper either.

Tooling note

No host-level blocking specifically prevented this search; the null result reflects a genuine absence in the indexed literature as searched.

Limits on what this shows

• Why no grade: Both conditions for ungraded were met: no Tier B or Tier C evidence was found on iron status specifically (ferritin, transferrin, hepcidin) for pioglitazone, and no circulating claim of iron depletion was found. Searches for "pioglitazone iron status ferritin transferrin," "pioglitazone iron ferritin hepcidin," and "pioglitazone hepcidin" returned zero relevant results across PubMed and general web search. The drug's documented hemoglobin/hematocrit fall (see Oxygen delivery/utilization, orange) is explicitly dilutional per its own labeled mechanism and does not by itself indicate iron loss; it is not used here to infer an iron-status effect.

Tooling note

Two of the four query phrasings for this category returned rate-limited (429) responses from the WebFetch channel on first attempt; both were retried successfully after a cooldown and returned genuine zero-result pages rather than blocked pages, so this is recorded as a literature gap, not solely a tooling gap.

Limits on what this shows

• Key negative/null findings: In the PCOS trial, most microbiota alterations associated with PCOS itself persisted after treatment regardless of arm, i.e. treatment did not fully normalize the dysbiotic pattern.
• At-risk subgroups: Not established for pioglitazone monotherapy in humans; the only human data are confounded by concurrent spironolactone and metformin.
• Counter-evidence on record: The confounded design of the only human trial is itself a limitation on attributing any effect to pioglitazone alone, and is stated as such rather than presented as isolated drug evidence.

Regulatory status

Not addressed in the FDA label.

Population evidence

Human: RCT in adolescent girls with PCOS (non-obese), oral contraceptive (n=15) vs. spironolactone + pioglitazone + metformin (n=15) vs. 31 controls, 1 year. The combination arm normalized abundance of bacterial Family XI, which correlated with hepato-visceral fat; other microbiota changes persisted regardless of treatment (Garcia-Beltran et al., Pediatr Obes 2021, PMID 32989872). Animal: pioglitazone monotherapy reshaped the gut microbiome and plasma metabolome while inhibiting pulmonary hypertension in male rats ( Physiol Rep 2025, PMID 39739369); a mouse high-fat-diet study of metformin+pioglitazone combination therapy also altered gut microbiota composition ( Front Pharmacol 2022, PMID 36304148).

Mechanism

Plausible but not fully characterized: PPAR-γ agonism affects intestinal epithelial and immune signaling that can secondarily shape microbial composition.

Counter-evidence held on record

Not evidence of microbiome harm; animal and confounded-human data trend toward a modulatory, largely protective direction in disease models. Too preliminary for any consumer-facing claim beyond a monitoring prompt.

Limits on what this shows

• Key negative/null findings: Label describes the change as stabilizing after the initial 4-12 week window rather than progressing, consistent with a one-time dilutional shift rather than ongoing loss.
• At-risk subgroups: Combination therapy raises edema incidence, and by extension this dilutional effect, most with insulin (15.3% edema vs. 7.0% placebo) and least with pioglitazone monotherapy (4.8% vs. 1.2% placebo).
• Counter-evidence on record: None found suggesting a true (non-dilutional) anemia mechanism specific to pioglitazone; this is explicitly distinguished from iron-deficiency anemia in the sources reviewed.

Regulatory status

FDA label states ACTOS "may cause decreases in hemoglobin and hematocrit," with mean declines of 2%-4% across clinical studies, occurring within 4-12 weeks and then stabilizing; anemia reported in ≤2% of combination-therapy patients in US double-blind trials.

Population evidence

Pooled data across ACTOS registration trials (monotherapy and combination therapy), Tier A regulatory source.

Mechanism

Named: plasma-volume expansion (hemodilution) secondary to the drug's fluid-retention effect, not true red-cell mass loss. StatPearls independently states the hemoglobin/hematocrit fall is "most likely due to hemodilution."

Counter-evidence held on record

Do not file this as iron-deficiency anemia. It is a dilutional, self-limited hemodynamic effect. Iron supplementation is not indicated on this basis alone; a persistent or worsening fall in hemoglobin should prompt a standard anemia workup rather than empiric iron.

Limits on what this shows

• Key negative/null findings: Pioglitazone also decreased some fatty-acid oxidation enzyme levels by ~10%-15% in the same tissue, indicating the effect is a rebalancing rather than a uniform increase in every mitochondrial protein.
• At-risk subgroups: Effect demonstrated specifically in type 2 diabetes with a documented baseline deficit; not established in people without diabetes.
• Counter-evidence on record: None identified specific to pioglitazone.

Regulatory status

Not addressed in the FDA label.

Population evidence

Human study, people with normal glucose tolerance vs. type 2 diabetes (baseline cohort 8 vs. 8, expanded cohort 24 vs. 24, 20 of the diabetic group randomized to 6 months of pioglitazone 15 mg/day). Diabetes lowered skeletal-muscle ATP5A protein by ~30% (p=0.006) versus controls; pioglitazone restored ATP5A, ETFA, CX6B1, and mitofilin protein abundance (p≤0.05). Metabolism 2020 (ScienceDirect, PII S0026049520302808).

Mechanism

Named: correction of diabetes-associated downregulation of oxidative-phosphorylation complex proteins, consistent with the PPAR-γ/PGC-1α biogenesis pathway seen in the adipose-tissue entry above.

Counter-evidence held on record

A restorative, disease-correcting effect, not evidence of ATP depletion by the drug. No supplement implication.